The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wahlsten, J. L.
Right arrow Articles by Ramakrishnan, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wahlsten, J. L.
Right arrow Articles by Ramakrishnan, S.
The Journal of Immunology, 1998, 161: 6761-6767.
Copyright © 1998 by The American Association of Immunologists

Antitumor Response Elicited by a Superantigen- Transmembrane Sequence Fusion Protein Anchored onto Tumor Cells1

Jennifer L. Wahlsten2,*, Charles D. Mills{dagger} and S. Ramakrishnan3,*

Departments of * Pharmacology and {dagger} Surgery, University of Minnesota, Minneapolis, MN 55455


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Superantigens stimulate T cells bearing certain TCR ß-chain variable regions when bound to MHC II molecules. We investigated whether the superantigen toxic shock syndrome toxin-1 (TSST1) could induce an antitumor immune response when anchored onto MHC II-negative tumor cells. Our approach was to facilitate association of TSST1 with cell membranes by fusing its coding region to the transmembrane region (TM) sequence of the proto-oncogene c-erb-B-2. TSST1-TM was expressed in bacteria with an N-terminal histidine tag and purified using nickel-agarose affinity chromatography. Purified TSST1-TM added to cultures of several different MHC II-negative tumor cells spontaneously associated with cell membranes, as detected by flow cytometry. Because superantigens can direct cell-mediated cytotoxicity against MHC II-positive cells, a TM fusion protein lacking the TSST1 MHC II binding domain (TSST88–194-TM) was also constructed. Tumor cells precoated with TSST1-TM or TSST88–194-TM stimulated proliferation of human peripheral blood lymphocytes in vitro whereas uncoated tumor cells did not. Mice preimmunized with TSST1-TM- or TSST88–194-TM-coated tumor cells mounted a systemic response that resulted in significant antitumor immunity as measured by regression of a parental tumor challenge. TSST1-TM and TSST88–194-TM fusion proteins represent a useful new strategy for attaching superantigens or potentially other proteins onto tumor cell surfaces without genetic manipulation.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Tumor cells often escape protective immune responses because they lack or down-regulate stimulatory surface Ags (1). Introduction of immunostimulatory Ags such as MHC I, MHC II, or B7-1 onto the surface of tumor cells can induce antitumor immunity as demonstrated by rejection of parental tumor in vivo (2). Typically, these approaches involve transfection of the relevant genes. However, transfection is time consuming, and primary tumor cells often do not grow well in vitro. Therefore, the practical application of this strategy to human tumors may be limited.

Alternatively, surface Ags can be introduced onto tumor cells without transfection through fusion with a glycosyl-phosphatidylinositol (GPI)4 signal sequence (3). Purified, recombinant GPI-linked fusion proteins incubated with tumor cells can passively re-anchor onto extracellular membranes. In vitro studies applying this approach demonstrated that GPI-anchored, Ag-presenting MHC I molecules effectively promoted T cell-mediated cytotoxicity (4), and GPI-anchored B7-1 (CD80) costimulated lymphocyte proliferation (5).

We sought to develop a strategy for passively attaching the superantigen toxic shock syndrome toxin-1 (TSST1) onto tumor cells. As a superantigen, TSST1 stimulates T cells bearing certain TCR Vß elements when bound as an unprocessed protein outside the antigenic groove of MHC II molecules (6). The subsequent polyclonal T cell expansion results in massive cytokine release, including IL-2, IFN-{gamma}, and TNF (7). Local release of IL-2 or IFN-{gamma} by transfected tumor cells can elicit systemic antitumor immunity (8). Cell anchoring of a superantigen such as TSST1 would place an immunostimulatory surface Ag on tumor cells capable of promoting local production of these and other cytokines. The potential of this strategy has been demonstrated in a study where mice immunized with tumor cells chemically linked to the superantigen Staphylococcal enterotoxin B developed specific antitumor immunity (9). However, covalently linking proteins onto cells has the potential limitation of altering cell function, and generally does not allow for a single point of attachment, nor for predictable orientation. Applying the aforementioned method of fusing TSST1 to a GPI signal sequence could result in predictable orientation and attachment. However, GPI linkage requires eukaryotic processing (10). Therefore, as a prokaryotic protein TSST1 is not well suited to a GPI-signal-sequence-fusion strategy for cell membrane anchoring. We sought to develop a strategy for passive anchoring that allowed TSST1 expression in a bacterial host.

In searching for an applicable method to achieve this end, Lin et al. (11) reported that addition of a synthetic peptide—composed of a signal peptide sequence and a nuclear localization sequence—to living eukaryotic cells resulted in its spontaneous cellular import (11). Cellular uptake of this nuclear localization sequence was primarily mediated by the hydrophobic region of the signal peptide. It has been demonstrated in Escherichia coli that hydrophobic segments can facilitate their own membrane insertion (12), and recent studies indicate this phenomenon also applies to transmembrane (TM) fragments of eukaryotic proteins (13). Since increasing hydrophobicity will change a translocating sequence into a stop-anchor sequence (14, 15), we hypothesized that fusing TSST1 to a hydrophobic TM sequence would permit it to passively anchor onto cell membranes of living cells. Here we show that a recombinant TSST1-transmembrane region chimera (HTSST1-TM) spontaneously associates with intact cells.

Superantigen-based antitumor strategies may offer therapeutic promise. However, because superantigens preferentially direct cytotoxicity against MHC II-positive cells (16, 17, 18), in vivo administration of intact superantigens in sufficiently therapeutic amounts risks unwanted cytotoxicity against normal cells. Therefore, successful employment of superantigens in tumor immunotherapy will likely require compromising their MHC II binding capabilities. Crystallographic studies have demonstrated that residues within the TSST1 N-terminal domain directly interact with MHC II molecules (19), and mutation analyses of TSST1 have localized residues critical for its superantigenic activity to the C-terminal domain (20, 21, 22). When expressed as a recombinant protein, the TSST1 C-terminal residues 88–194 do not bind to MHC II molecules yet retain superantigenic activity (23). Therefore, a TM fusion protein having only the TSST1 C-terminal residues 88–194 was also constructed (HTSST88–194-TM or HT84-TM). Here we show that cell-anchored HTSST1-TM and HT84-TM exhibit potent biological activity in vitro and in vivo, as measured by lymphocyte proliferation and tumor immunization, respectively.

Passive anchoring of superantigen and potentially other TM fusion proteins offers a novel strategy for addition of immunostimulatory molecules onto tumor cells.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Reagents

The prokaryotic expression vector pET17bH, with an N-terminal histidine sequence, has been described (24). A TSST1 subclone was provided by Dr. P. M. Schlievert (University of Minnesota, Minneapolis). Enzymes for molecular cloning were purchased from New England Biolabs (Beverly, MA). Oligonucleotides were synthesized by Integrated DNA Technologies (Coralville, IA). FITC-labeled goat-anti-rabbit IgG Abs were obtained from Sigma (St. Louis, MO). Murine cell lines EL4 and Lewis lung carcinoma (LLC) (C57BL/6, H-2b) and the plasmid encoding c-erb-B-2 were purchased from the American Type Culture Collection (Manassas, VA). Raji MHC II-negative mutant RJ2.2.5 was obtained from Dr. J. M. Boss (Emory University, Atlanta, GA) with permission of Dr. R. Accolla (Advanced Biotechnology Center, Genova, Italy). The murine P815 mastocytoma (DBA/2, H-2d) used has been described (25, 26, 27). Female C57BL/6 x DBA/2 (B6D2F1, H-2b/d) 8-wk-old mice were purchased from Taconic Farms (Germantown, NY) and housed within University of Minnesota animal facilities. The P815 tumor grows progressively and has been shown to generate a tumor-specific response in B6D2F1 mice as well as in the parental strain (25, 26, 27).

Construction and subcloning of the TSST1-TM and T84-TM fusion sequences into pET 17bH

The coding sequences for TSST1 or TSST88–194 were fused to the TM-encoding sequence of c-erb-B-2 using splice overlap extension PCR (28) and the following primers, with restriction sites in bold and an underlined stop codon: primer 1, 5'-CCCCATATGTCTACAAACGATAATATAAAGGAT-3'; primer 2, 5'-TCTCTGCTCGGCACTAGTATTAATTTCTGC3'; primer 3, 5'-GCAGAAATTAATACTAGTGCCGAGCAGAGA-3'; primer 4, 5'-CCCCTCGAGTTACATCGTGTACTTCCG-3'; primer 5, 5'-CCCCATATGGTTACAAATACTGAA-3'.

The TSST1 coding sequences were amplified from MNT subclone 6101 (29) using primers 1 and 2 or 5 and 2. The DNA sequence corresponding to amino acid residues 644–687 of c-erb-B-2, inclusive of the TM region, was amplified from plasmid clone pCER204 (30) using primers 3 and 4. The amplified fragments corresponding to TSST1 (610 bp), T84 (320 bp), and c-erb-B-2 (160 bp) were purified and used as templates in subsequent PCRs. The TSST1-TM fusion sequences were PCR-amplified from the TSST1 or T84 and c-erb-B-2 fragments using primers 1 and 4 or 5 and 4, respectively. The amplified fragments (740 bp and 450 bp) were digested with NdeI and XhoI and ligated into predigested pET 17bH. Positive clones were confirmed through NdeI/XhoI redigestion and dsDNA sequencing before transforming into host strain BL21(DE3) pLysS for expression.

Expression of HTSST1-TM and HT84-TM in E. coli

Expression of HTSST1-TM and HT84-TM in E. coli was adapted from a described protocol (31, 32). Overnight cultures of transformed BL21(DE3) pLysS cells were inoculated 1:40 into 1 liter of M9-ZB medium (33) supplemented with 2% glucose, 100 µg/ml ampicillin, and 34 µg/ml chloramphenicol. Cultures were grown to an A600 of 0.8–1.0 with continuous shaking at 37°C before transcription was induced with isopropyl ß-D-thiogalactopyranoside (IPTG, 0.4 mM). Cells were harvested after 2-h induction, the cell pellet was resuspended in 80 ml sonication buffer (300 mM NaCl/50 mM sodium phosphate, pH 8/1% Triton X-100), and was frozen at -80°C.

Purification of HTSST1-TM and HT84-TM

Proteins expressed from pET 17bH have 10 sequential histidine residues at the amino terminus, allowing purification over nickel-agarose. The frozen cell lysate was thawed, sonicated and clarified by centrifugation at 28,000 x g for 30 min. The clarified lysate was diluted with an equal volume of sonication buffer and loaded batchwise onto nickel agarose over 4 h at 4°C. The resin was rinsed with sonication buffer, placed in a column support, and rinsed with wash buffer (300 mM NaCl/50 mM sodium phosphate, pH 8/15% glycerol). Nonspecifically bound host proteins eluted in wash buffer containing 100 mM imidazole. HTSST1-TM and HT84-TM bound to the resin was eluted in wash buffer containing 300 mM imidazole and dialysed into PBS (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.4 mM KH2PO4). Purified, dialysed protein was concentrated, aliquoted, and stored at -80°C. Protein concentrations were determined using BCA assay reagents (34). Relative protein purity was determined by densitometric measurement of Coomassie brilliant blue R-250-stained 12% SDS polyacrylamide gels.

Association of HTSST1-TM with MHC II-negative tumor cells

Tumor cells were resuspended to 0.5–1.0 x 106 cells/ml in medium containing 2.5% FCS. Purified HTSST1-TM was added to a final concentration of 0.33–1.67 µM and incubated for 4 h at 37°C. Cells were rinsed and analyzed for the presence of HTSST1 on their surface by flow cytometry. In the negative control, cells not exposed to HTSST1-TM were incubated with primary and secondary Abs. Anchored HTSST1-TM was detected with purified IgG from rabbit serum against TSST1 residues 88–194 ({alpha}T84), added at a 1:300 dilution with 3% normal goat serum. Bound {alpha}T84 was detected with FITC goat anti-rabbit IgG added at a 1:200 dilution. Cells were gated for viability using propidium iodide and 2–10 x 103 events were measured for positive fluorescence by flow cytometry.

The presence of HTSST1-TM on the human ovarian carcinoma cell line, MA 148 (35), was also visualized by in situ immunohistochemistry. MA 148 cells were seeded at low density onto glass coverslips and grown for 24–48 h. The cells were then incubated for 4 h at 37°C in medium containing 1 µM HTSST1-TM and 2.5% serum. Cells were rinsed with PBS and fixed for 10 min at room temperature (4% paraformaldehyde, 2% sucrose in PBS). Detection of HTSST1-TM was done using the Abs described above. Coverslips were mounted onto glass slides. Images were captured with a x10 neofluor objective on a Nikon Diaphot 300 inverted microscope connected to a Photometrics PXL cooled CCD camera (Tucson, AZ) using the computer program IPLab Spectrum (Signal Analytics, Vienna, VA).

Biological activity of HTSST1-TM and HT84-TM in vitro

The in vitro biological activity of HTSST1-TM- or HT84-TM-coated tumor cells was measured using a lymphocyte proliferation assay. PBL were isolated from the blood of healthy donors over a Histopaque 1077 gradient (Sigma) and aliquoted to 2 x 105 cells/well in 96-well U-bottom plates. The PBLs were incubated in 0.2 ml RPMI 1640 medium containing 5% FCS and irradiated (10,000 rad) coated or uncoated MA 148 cells at a 1:1 or 1:2 tumor cell to PBL ratio. MA 148 cells were coated with either 1.67 µM of HTSST1-TM or HT84-TM, or serial 5-fold dilutions of HTSST1-TM. After 72-h incubation (37°C, 5% CO2), cells were labeled with [3H]thymidine (1 µCi/well) for 18 h before harvesting. Incorporation of [3H]thymidine was determined using a liquid-scintillation counter.

Biological activity of HTSST1-TM and HT84-TM in vivo

The in vivo biological activity of HTSST1-TM- or HT84-TM-coated tumor cells was determined using an established immunization protocol (25, 26, 27). Five mice were in each treatment group. P815 cells (1 x 106 cells/ml) were incubated in serum-free medium alone or with HTSST1-TM (0.17 or 1.67 µM) or HT84-TM (0.03, 0.17, or 0.85 µM) as described above. Tumor cells were then rinsed, resuspended at 1 x 107 cells/ml, and treated with 50 µg/ml mitomycin C (Mit C) for 1 h at 37°C. Mice were immunized s.c. in the foot with superantigen-coated or control tumor cells (1 x 107 cells in 50 µl/mouse). At 21 days postimmunization, antitumor immunity was determined by challenging mice intradermally in the axillary region with 5 x 105 or 1 x 106 viable P815 tumor cells. Previous studies using this tumor immunization model have shown that the primary P815 tumor-specific CTL response disappears by about 14–17 days, so that by 21 days a state of long-term memory immunity is present. Also, by waiting 21 days we reduce the possible contribution of nonspecific effects due to the superantigen. Bisecting tumor diameters were measured with calipers every 2–3 days. Mice were sacrificed when tumor diameters exceeded 15 mm. All control mice developed progressively growing tumors. Some mice in the treatment groups did not, and of the tumors that did develop, some progressed and others regressed. Therefore, significant differences between control and test groups were determined using the nonparametric Wilcoxon Rank Sum test.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Cloning and expression of HTSST1-TM and HT84-TM

The chimeric TSST1 or T84/c-erb-B-2 TM region DNA sequences were created by splice overlap extension (28) and subcloned into pET 17bH as described in Materials and Methods and depicted in Fig. 1GoA. Control of the chromosomally located T7 polymerase gene in E. coli host strain BL21(DE3) is not completely stringent, resulting in basal expression of proteins directed by the T7 promoter (33). Considerable levels of HTSST1 were expressed in BL21(DE3) without induction of T7 polymerase by IPTG (32). HTSST1-TM and HT84-TM are toxic to bacteria which express them, but can be successfully over-expressed if protein production is stringently repressed during growth. Expression of HTSST1-TM and HT84-TM was achieved when transforming the TSST1-TM/pET 17bH plasmids into E. coli host strain BL21(DE3) pLysS and growing cultures in 2%, rather than 0.4%, glucose (31). Successful expression of TSST1-TM and T84-TM under these more stringent growth conditions is shown on a Coomassie brilliant blue-stained 12% SDS-polyacrylamide gel of whole bacterial lysates from induced and uninduced cultures (Fig. 1GoB). Only IPTG-induced cultures over-expressed recombinant protein.



View larger version (41K):
[in this window]
[in a new window]
  		FIGURE 1. A, Schematic of the HTSST1-TM and HT84-TM proteins, with sequences created by splice overlap PCR. Arrows indicate relative positions of the primers. Boxes are not proportional. Subcloning of the fusion sequences into pET 17bH results in a N-terminal histidine sequence. B and C, Representative 12% SDS-PAGE analyses showing expression and purification of HTSST1-TM and HT84-TM. B, Expression of HTSST1, HTSST1-TM, and HT84-TM in host BL21(DE3) pLysS. Pelleted 1 ml aliquots of 3 ml minicultures were directly resuspended in 0.5 ml sample buffer (50 mM Tris-HCl (pH 6.8), 100 mM DTT, 2% SDS, 0.1% bromophenol blue, 10% glycerol); 20 µl were loaded per well. Lane 1, uninduced HTSST1; lane 2, induced HTSST1; lane 3, uninduced HTSST1-TM; lane 4, induced HTSST1-TM; lane 5, uninduced HT84-TM; lane 6, induced HT84-TM. C, Purified HTSST1-TM (5 µg loaded) and HT84-TM (2 µg loaded).

 
Purification of HTSST1-TM and HT84-TM

HTSST1-TM and HT84-TM were extracted from bacterial cell membranes using the nonionic detergent Triton X-100 (1%) because refolded preparations extracted using denaturing agents such as urea or guanidine-HCl did not induce proliferation. Protein in the clarified bacterial lysate loaded more efficiently onto the nickel-agarose resin when incubated batchwise. The resin was then thoroughly rinsed while on an immobilized support with a wash buffer containing glycerol. A rinse containing a comparatively high concentration of imidazole (100 mM) was necessary to elute host proteins nonspecifically associating with either the TM fusion proteins or the resin. Upon addition of 300 mM imidazole, HTSST1-TM or HT84-TM eluted between 4 and 20 ml. Positive fractions were pooled and dialysed against PBS. Fig. 1GoC depicts a representative Coomassie brilliant blue-stained 12% SDS-polyacrylamide gel showing purified HTSST1-TM and HT84-TM. This one-step purification strategy yielded per liter of bacterial culture 2 mg of HTSST-TM or 0.2 mg of HT84-TM with an average relative purity of 88%.

HTSST1-TM associates with MHC II-negative tumor cells

Superantigens normally bind MHC class II molecules on cells (6). The ability of HTSST1-TM to associate with cells through the TM region but not by MHC II binding was evaluated on four different MHC II-negative tumor cell lines: MA 148, RJ2.2.5, LLC, and EL4. RJ2.2.5 is a MHC II-negative mutant of the human B cell lymphoma, Raji (36). Murine cell lines EL4, LLC, P815 and the human ovarian carcinoma MA 148 are all MHC class II-negative, even after exposure to IFN-{gamma} (data not shown; 37 .

Spontaneous anchoring of HTSST1-TM onto the different tumor cell lines was determined by flow cytometry. The cells were incubated with HTSST1-TM or HTSST1 at 37°C, rinsed of unbound protein, and immediately prepared for flow cytometry. As shown in Fig. 2Go, HTSST1-TM spontaneously anchored onto all tumor cell lines tested. This association requires the TM region, because recombinant native HTSST1 did not bind to RJ2.2.5, MA 148, or LLC cells (Fig. 2Go). The cell lines tolerated serum deprivation variably, regardless of exposure to HTSST1-TM. Addition of serum concentrations up to 2.5% did not interfere with HTSST1-TM association and improved viability. MA 148 cells prepared for flow cytometry 22 h after incubation with HTSST1-TM retained a fluorescence intensity at 25% the level of treated cells that were analyzed directly (data not shown). This is most likely due to internalization or shedding of HTSST1 into the medium, because preventing cell division with Mit C did not change this result. HTSST1-TM did not significantly associate with cells when incubated at 4°C (data not shown). To determine the distribution of HTSST1-TM association among coated cells and retention of cell integrity after incubation, anchored HTSST1-TM on MA 148 was also visualized by indirect immunofluorescence (Fig. 3Go).



View larger version (24K):
[in this window]
[in a new window]
  		FIGURE 2. HTSST1-TM spontaneously associates with MHC II-negative tumor cell lines. Coated tumor cells MA 148 (7500 events), RJ2.2.5 (10,000 events), LLC (7500 events), and EL4 (2000 events) were analyzed by flow cytometry using purified {alpha}T84 Ig, and FITC goat anti-rabbit Ig. Fluorescence was measured on cells exposed to serum-free medium (···), 0.75 µM HTSST1(---), or HTSST1-TM (——). HTSST1 binding to EL4 cells was not tested.

 


View larger version (160K):
[in this window]
[in a new window]
  		FIGURE 3. Visualizing HTSST1-TM on MA 148 cells by indirect immunofluorescence. MA 148 cells attached to glass coverslips were incubated in medium containing 2.5% serum without (A and B) or with 1.0 µM HTSST1-TM (C and D) for 4 h. Cells were rinsed, fixed, and incubated first with purified {alpha}T84 Ig, then with FITC goat anti-rabbit Ig. A and C, Phase-contrast exposures; B and D, fluorescence exposures. Bar = 30 µm.

 
MA 148 cells coated with HTSST1-TM or HT84-TM stimulate lymphocyte proliferation

The in vitro biological activity of HTSST1-TM- or HT84-TM-coated MA 148 cells was determined by lymphocyte proliferation assays. Fig. 4GoA shows the results of an experiment where MA 148 cells were coated with 1.67 µM of HTSST1-TM or HT84-TM before being cultured with PBLs. MA 148 cells coated with either HTSST1-TM- or HT84-TM-stimulated lymphocyte proliferation (Fig. 4GoA). To determine whether cells coated with smaller concentrations of protein were biologically active, MA 148 cells were coated with 5-fold serial dilutions of HTSST1-TM before being cultured with PBLs (Fig. 4GoB). Preincubating MA 148 cells with as little as 1 nM HTSST1-TM induced significant PBL proliferation vs uncoated MA 148 cells (p < 0.004, Fig. 4GoB). These results show that membrane bound HTSST1-TM and HT84-TM can induce lymphocyte proliferation in vitro.



View larger version (25K):
[in this window]
[in a new window]
  		FIGURE 4. HTSST1-TM- and HT84-TM-coated MA 148 cells stimulate proliferation of human PBLs. A, MA 148 cells were coated with 1.67 µM HTSST1-TM or HT84-TM, irradiated, and added at a 1:1 tumor/lymphocyte (T:L) ratio to 2 x 105 PBLs/well in a 96-well plate. B, Coated MA 148 cells were preincubated with 5-fold serial dilutions of HTSST1-TM and added at a 1:2 T:L ratio. Values on the y-axis represent the average cpm ± SD of triplicate cultures from two independent experiments. Background values of lymphocytes alone have been subtracted. *, p < 0.004 vs uncoated MA 148, two-tailed Student’s t test.

 
Immunization with HTSST1-TM- or HT84-TM-coated P815 cells induces antitumor immunity

The in vivo biological activity of HTSST1-TM- or HT84-TM-coated murine P815 cells was determined using an established immunization protocol that measures a secondary response against parental tumor challenge (25, 26, 27). Mice (five per group) were immunized in the footpad with Mit C-treated P815 cells or P815 cells precoated with varying concentrations of HTSST1-TM or HT84-TM. We used P815 tumor cells for in vivo experiments because it is a well-characterized immunogenic tumor (38). Twenty-one days postimmunization, growth of parental tumor challenge was measured at a distant site. Mice preimmunized with either HTSST1-TM- or HT84-TM-coated P815 tumor cells exhibited significant antitumor immunity. We show in Fig. 5GoA that preimmunization of mice with P815 cells incubated with either 1.67 µM or 0.17 µM HTSST1-TM displayed antitumor immunity. Mice preimunized with P815 cells coated with 0.17 µM HTSST1-TM elicited a significant antitumor response in comparison to mice preimmunized with uncoated P815 tumor cells (p <= 0.03). The average diameters for this group reflect a reduced tumor incidence (three of five mice), delayed appearance of tumors that did develop, and partial regression of one tumor that eventually completely regressed (Fig. 5GoB). Mice preimmunized with P815 cells incubated with 1.67 µM of HTSST1-TM all initially developed tumor; however, the average value presented for this group reflects the complete regression of one tumor and the partial regression of two others (Fig. 5GoA). Because the higher dose of HTSST1-TM was less effective and because we challenged at a site distant from immunization after 21 days, the antitumor immunity observed was very likely tumor specific. The mice with tumors that completely regressed (one from each test group) were rechallenged with 1 x 106 parental P815 cells 87 days postimmunization and neither developed tumor (data not shown).



View larger version (33K):
[in this window]
[in a new window]
  		FIGURE 5. Mice immunized with HTSST1-TM- or HT84-TM-coated P815 cells mount a systemic antitumor response against challenge with parental tumor. Five mice were in each treatment group. P815 cells (1 x 106/ml) were incubated with HTSST1-TM (1.67 or 0.17 µM), or HT84-TM (0.85, 0.17, or 0.03 µM) as described in Materials and Methods. B6D2F1 mice were then immunized with 1 x 107 HTSST1-TM- (A) or HT84-TM- (C) coated or uncoated Mit C-treated P815 cells and challenged 21 days later by axillary intradermal injection with 5 x 105 (A) or 1 x 106 (C) parental P815. B and D, P815 tumor growth rejection by the five individual mice treated with P815 cells coated with either 0.17 µM HTSST1-TM or 0.85 µM HT84-TM, respectively. Values on the y-axis represent the average bisecting tumor diameters. *, p <= 0.03 vs P815 immunized control, Wilcoxon Rank Sum test.

 
We show in Fig. 5GoC that HT84-TM also increased the immunogenicity of P815 tumor cells. Mice preimmunized with P815 cells incubated with 0.85 µM HT84-TM exhibited significant antitumor immunity in comparison to mice preimmunized with uncoated P815 tumor cells (p <= 0.02). Of the five mice in this group, one did not develop tumor and two developed tumors that completely regressed (Fig. 5GoD). All mice preimmunized with P815 cells incubated with 0.17 µM HT84-TM initially developed tumor, but two tumors completely regressed and one partially regressed (Fig. 5GoC). When comparing the antitumor responses elicited by equimolar concentrations of HT84-TM and HTSST1-TM (0.17 µM of HTSST1-TM or HT84-TM), HTSST1-TM-coated cells were more potent immunogens, correlating with the in vitro proliferation experiments (Fig. 4GoA). Together, these results suggest that HTSST1-TM- or HT84-TM-coated P815 tumor cells can stimulate systemic antitumor immunity. Optimizing the immunization protocol should further improve the antitumor immunity induced by HTSST1-TM- or HT84-TM- anchored tumor cells.


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
In this study, we describe a novel and effective method for incorporating the superantigen TSST1, and perhaps other proteins, onto the surface of tumor cells. Fusing a TM sequence onto TSST1 resulted in its spontaneous association with four different tumor cell lines. Because the hydrophobic TM sequence mediates this passive anchoring, HTSST1-TM and HT84-TM should associate with membranes of most cells or tumors. Anchored HTSST1-TM and HT84-TM were biologically active in vitro, as shown by the ability of coated MA 148 cells to elicit proliferation of PBLs.

TSST1 is a powerful immunostimulant, and tumor cells coated with concentrations below the levels of detection still induced a biological response. Incubating concentrations of at least 25 nM HTSST1-TM could be detected on MA 148 cells by flow cytometry (data not shown). Yet coated MA 148 cells still stimulated significant PBL proliferation when incubated with HTSST1-TM concentrations 25-fold less than this. Incubating MA 148 cells with as little as 1 nM HTSST1-TM elicited a significant proliferative response in vitro (Fig. 4GoB). This result is not surprising when considering that soluble TSST1 concentrations as low as 2 pM will induce significant proliferation of human peripheral blood mononuclear cells in vitro (39).

Coating tumor cells with smaller concentrations of HTSST1-TM is not only more desirable for minimizing toxicity with the potential therapeutic application of this strategy but also resulted in better systemic antitumor immunity. Immunization with P815 tumor cells coated with 0.17 µM HTSST1-TM significantly inhibited subsequent onset and growth of a parental tumor challenge, whereas P815 cells incubated with 1.67 µM was less effective. It is not totally unexpected that P815 cells coated with higher concentrations of HTSST1-TM were less effective immunogens. Miethke et al. (40) have demonstrated a dose-response relationship between superantigen-induced T cell stimulation or inhibition in vivo, where increasing superantigen doses resulted in anergy and deletion. The ability of high doses of superantigen to cause T cell anergy or deletion in vivo has also been documented by others (41, 42, 43, 44). Thus, P815 cells coated with the highest concentration of HTSST1-TM (1.67 µM) may have induced a diminished antitumor response because of T cell anergy or deletion. A possible mechanism for this effect might be the ability of TSST1 to directly stimulate macrophages through MHC II engagement (45, 46, 47). Excessive stimulation of macrophages has been shown to have immunosuppressive consequences (48), in part mediated by nitric oxide and TNF-{alpha}, that can interfere with a productive antitumor response (26, 49).

From a therapeutic perspective, we hypothesized that coating tumor cells with HTSST1-TM would focus a powerful T cell response to the context of the altered (and unaltered) cell while minimizing potentially toxic systemic exposure. However, immunologic processing and the intrinsic dynamic fluidity of cell membranes will make these imposed constraints inherently imperfect. Therefore, it is probable that in vivo both released and cell-bound HTSST1-TM contribute to the antitumor response. By coating tumor cells with HT84-TM, we sought to minimize cytotoxicity to neighboring MHC II-positive cells that could potentially be caused by dissociation of HTSST1-TM from the intact cell. That membrane-bound HTSST1-TM or HT84-TM contribute significantly to the in vivo antitumor response observed is indirectly demonstrated by the ability of HT84-TM-coated tumor cells to protect against subsequent tumor challenge. Unable to bind MHC II, free TSST88–194 should not encourage formation of a ternary primary signaling complex or the T cell costimulatory signals provided by APC contact and necessary for long-term immunity (23). Whereas 100-fold greater molar concentrations of free HT84 were required to elicit a response equivalent to HTSST1 in vitro (23), only 5-fold greater concentrations of membrane-associated HT84-TM were required to elicit a secondary response equivalent to HTSST1-TM in vivo.

An antitumor strategy that anchors a superantigen on MHC II-negative tumor cells assumes T cell stimulation, but which circumvents conventionally defined MHC "presentation." The stimulatory mechanism likely involves a third party APC, which minimally would provide necessary costimulatory signals. Numerous studies have shown the ability of superantigens to elicit MHC II-independent T cell stimulation in vitro as long as costimulatory signals were provided (50, 51, 52, 53). In addition, TSST1 promoted proliferation of isolated CD4+ T cells in vitro when presented by immobilized mAbs against the MHC II binding region (54). Furthermore, it has been demonstrated in several reports that anchoring Staphylococcal enterotoxin A (SEA) onto MHC II-negative tumor cells through Abs directs T cell-mediated cytotoxicity against these tumors (55, 56, 57, 58). These results suggest that superantigens can induce immunostimulation in the absence of MHC II molecules, and that artificially anchoring a superantigen onto a cell surface can substitute for MHC II presentation.

That superantigens can induce MHC II-independent immunostimulation is therapeutically relevant. Because superantigens have been shown to generally direct T cell cytotoxicity against MHC II-positive cells on which they are bound (59), clinically feasible application of superantigen-based antitumor strategies will likely require compromising MHC II binding capabilities. Indeed, SEA mutants with diminished MHC II binding affinities have been tested in vitro and in vivo. A SEA mutant unable to engage MHC II molecules promoted cell-mediated cytotoxicity in vitro indistinguishably from native SEA when anchored onto cells with Ab (60). Tumor-bearing mice treated with this Ab-directed SEA mutant mounted antitumor responses with reduced toxicity (61). HT84-TM contains the TSST1 C-terminal residues 88–194 with amino acids critical for superantigenicity while lacking the MHC II binding domain (19, 20, 21, 22). In vitro experiments show that soluble TSST88–194 expressed as a recombinant protein does not bind MHC II molecules (23). Therefore, HT84-TM should induce an antitumor response without binding MHC II molecules and with reduced cytotoxicity against normal MHC II-positive cells.

TSST1-TM fusion proteins represent a novel method for passively introducing immunostimulatory proteins onto cells.


   Acknowledgments
 
We thank Phuong Oanh Stephan for capturing the microscopic images, and Colin Campbell and Christopher Pennell for their critical reading of this manuscript.


   Footnotes
 
1 J.L.W. was a Howard Hughes Medical Institute Predoctoral Fellow. C.D.M. is supported by National Institutes of Health PO1GM50150. Back

2 Current address: Laboratory of Immunology, National Eye Institute, National Institutes of Health, Building 10, Room 10N222, Bethesda, MD 20892-1857. Back

3 Address correspondence and reprint requests to Dr. S. Ramakrishnan, Department of Pharmacology, University of Minnesota, 3-249 Millard Hall, 435 Delaware Street SE, Minneapolis, MN 55455. Back

4 Abbreviations used in this paper: GPI, glycosyl-phosphatidylinositol; TSST1, toxic shock syndrome toxin-1; H, histidine tag; TM, transmembrane; T84, TSST1 residues 88–194; LLC, Lewis lung carcinoma; IPTG, isopropyl ß-D-thiogalactopyranoside; Mit C, mitomycin C; SEA, Staphylococcal enterotoxin A. Back

Received for publication April 14, 1998. Accepted for publication August 11, 1998.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Melief, C. J. M.. 1992. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv. Cancer Res. 58:143.[Medline]
  2. Baskar, S.. 1996. Gene-modified tumor cells as cellular vaccine. Cancer Immunol. Immunother. 43:165.[Medline]
  3. Tykocinski, M. L., D. R. Kaplan, M. E. Medof. 1996. Antigen-presenting cell engineering: the molecular toolbox. Am. J. Pathol. 148:1.[Medline]
  4. Huang, J.-H., R. R. Getty, F. V. Chisari, P. Fowler, N. S. Greenspan, M. L. Tykocinski. 1994. Protein transfer of preformed MHC-peptide complexes sensitizes target cells to T cell cytolysis. Immunity 1:607.[Medline]
  5. McHugh, R. S., S. N. Ahmed, Y.-C. Wang, K. W. Sell, P. Selvaraj. 1995. Construction, purification, and functional incorporation on tumor cells of glycolipid-anchored human B7-1 (CD80). Proc. Natl. Acad. Sci. USA 92:8059.[Abstract/Free Full Text]
  6. Marrack, P., J. Kappler. 1990. The staphylococcal enterotoxins and their relatives. Science 248:705.[Abstract/Free Full Text]
  7. Chatila, T., P. Scholl, F. Spertini, N. Ramesh, N. Trede, R. Fuleihan, R. S. Geha. 1991. Toxic shock syndrome toxin-1, toxic shock, and the immune system. Curr. Top. Microbiol. Immunol. 174:63.[Medline]
  8. Pardoll, D. M.. 1995. Parakrine cytokine adjuvants in cancer immunotherapy. Annu. Rev. Immunol. 13:399.[Medline]
  9. Shimizu, M., A. Yamamoto, H. Nakano, A. Matsuzawa. 1996. Augmentation of antitumor immunity with bacterial superantigen, staphylococcal enterotoxin B-bound tumor cells. Cancer Res. 56:3731.[Abstract/Free Full Text]
  10. Englund, P. T.. 1993. The structure and biosynthesis of glycosyl phosphatidylinositol protein anchors. Annu. Rev. Biochem. 62:121.[Medline]
  11. Lin, Y.-Z., S.-Y. Yao, R. A. Veach, T. R. Torgerson, J. Hawiger. 1995. Inhibition of nuclear translocation of transcription factor NF-{kappa}B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J. Biol. Chem. 270:14255.[Abstract/Free Full Text]
  12. von Heijne, G.. 1994. Membrane proteins: from sequence to structure. Annu. Rev. Biophys. Biomol. Struct. 23:167.[Medline]
  13. Popot, J.-L., M. Saraste. 1995. Engineering membrane proteins. Curr. Opin. Biotechnol. 6:394.[Medline]
  14. Davis, N. G., P. Model. 1985. An artificial anchor domain: hydrophobicity suffices to stop transfer. Cell 41:607.[Medline]
  15. Chen, H., D. A. Kendall. 1995. Artificial transmembrane segments: requirements for stop transfer and polypeptide orientation. J. Biol. Chem. 270:14115.[Abstract/Free Full Text]
  16. Fleischer, B., H. Schrezenmeier. 1988. T cell stimulation by staphylococcal enterotoxins. J. Exp. Med. 167:1697.[Abstract/Free Full Text]
  17. Herrmann, T., J. L. Maryanski, P. Romero, B. Fleischer, H. R. MacDonald. 1990. Activation of MHC class I-restricted CD8+ CTL by microbial T cell mitogens: dependence upon MHC class II expression of the target cells and Vß usage of the responder T cells. J. Immunol. 144:1181.[Abstract]
  18. Dohlsten, M., P. A. Lando, G. Hedlund, J. Trowsdale, T. Kalland. 1990. Targeting of human cytotoxic T lymphocytes to MHC class II-expressing cells by staphylococcal enterotoxins. Immunology 71:96.[Medline]
  19. Kim, J., R. G. Urban, J. L. Strominger, D. C. Wiley. 1994. Toxic shock syndrome toxin-1 complexed with a class II major histocompatibility molecule HLA-DR1. Science 266:1870.[Abstract/Free Full Text]
  20. Blanco, L., E. M. Choi, K. Connolly, M. R. Thompson, P. F. Bonventre. 1990. Mutants of staphylococcal toxic shock syndrome toxin 1: mitogenicity and recognition by a neutralizing monoclonal antibody. Infect. Immun. 58:3020.[Abstract/Free Full Text]
  21. Hurley, J. M., R. Shimonkevitz, A. Hanagan, K. Enney, E. Boen, S. Malmstrom, B. L. Kotzin, M. Matsumura. 1995. Identification of class II MHC and T cell receptor binding sites in the superantigen toxic shock syndrome toxin-1. J. Exp. Med. 181:2229.[Abstract/Free Full Text]
  22. Murray, D. L., C. A. Earhart, D. T. Mitchell, D. H. Ohlendorf, R. P. Novick, P. M. Schlievert. 1996. Localization of biologically important regions on toxic shock syndrome toxin 1. Infect. Immun. 64:371.[Abstract]
  23. Wahlsten, J. L., S. Ramakrishnan. 1998. Separation of function between the domains of toxic shock syndrome toxin-1. J. Immunol. 160:854.[Abstract/Free Full Text]
  24. Mohanraj, D., D. Fryxell, S. Ramakrishnan. 1995. A novel method to purify immunotoxins from free antibodies using modified recombinant toxins. J. Immunol. Methods 182:165.[Medline]
  25. Mills, C., R. North, E. Dye. 1981. Mechanisms of anti-tumor action of Corynebacterium parvum. II. Potentiated cytolytic T cell response and its tumor-induced suppression. J. Exp. Med. 154:621.[Abstract/Free Full Text]
  26. Mills, C., J. Shearer, R. Evans, M. Caldwell. 1992. Macrophage arginine metabolism and the inhibition or stimulation of cancer. J. Immunol. 149:2709.[Abstract]
  27. Dye, E., R. North, C. Mills. 1981. Mechanisms of anti-tumor action of Corynebacterium parvum. I. Potentiated tumor-specific immunity and its therapeutic limitations. J. Exp. Med. 154:609.[Abstract/Free Full Text]
  28. Horton, R. M., H. D. Hunt, S. N. Ho, J. K. Pullen, L. R. Pease. 1989. Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. Gene 77:61.[Medline]
  29. Kreiswirth, B. N., S. Löfdahl, M. J. Betley, M. O’Reilly, P. M. Schlievert, M. S. Bergdoll, R. P. Novick. 1983. The toxic shock syndrome exotoxin structural gene is not detectably transmitted by a prophage. Nature 305:709.[Medline]
  30. Yamamoto, T., S. Ikawa, T. Akiyama, K. Semba, N. Nomura, N. Miyajima, T. Saito, K. Toyoshima. 1986. Similarity of protein encoded by the human e-erb-B-2 gene to epidermal growth factor receptor. Nature 319:230.[Medline]
  31. Li, B.-Y., A. E. Frankel, S. Ramakrishnan. 1992. High-level expression and simplified purification of recombinant ricin A chain. Protein Expression Purif. 3:386.[Medline]
  32. Wahlsten, J. L., S. Ramakrishnan. 1996. Expression and purification of recombinant toxic-shock-syndrome toxin 1. Biotechnol. Appl. Biochem. 24:155.
  33. Studier, F. W., B. A. Moffatt. 1986. Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes. J. Mol. Biol. 189:113.[Medline]
  34. Smith, P. K., R. I. Krohn, G. T. Hermanson, A. K. Mallia, F. H. Gartner, M. D. Provenzano, E. K. Fujimoto, N. M. Goeke, B. J. Olson, D. C. Klenk. 1985. Measurement of protein using bicinchoninic acid. Anal. Biochem. 150:76.[Medline]
  35. Olson, T. A., D. Mohanraj, L. F. Carson, S. Ramakrishnan. 1994. Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res. 54:276.[Abstract/Free Full Text]
  36. Accolla, R. S.. 1983. Human B cell variants immunoselected against a single Ia antigen subset have lost expression of several Ia antigen subsets. J. Exp. Med. 157:1053.[Abstract/Free Full Text]
  37. Townsend, S. E., F. W. Su, J. M. Atherton, J. P. Allison. 1994. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res. 54:6477.[Abstract/Free Full Text]
  38. North, R.. 1984. The murine antitumor immune response and its therapeutic manipulation. Adv. Immunol. 35:89.[Medline]
  39. Poindexter, N. J., P. M. Schlievert. 1985. Toxic-shock-syndrome toxin 1-induced proliferation of lymphocytes: comparison of the mitogenic response of human, murine, and rabbit lymphocytes. J. Infect. Dis. 151:65.[Medline]
  40. Miethke, T., C. Wahl, H. Gaus, K. Heeg, H. Wagner. 1994. Exogenous superantigens acutely trigger distinct levels of peripheral T cell tolerance/immunosuppression: dose-response relationship. Eur. J. Immunol. 24:1893.[Medline]
  41. Wahl, C., T. Miethke, K. Heeg, H. Wagner. 1993. Clonal deletion as direct consequence of an in vivo T-cell response to bacterial superantigen. Eur. J. Immunol. 23:1197.[Medline]
  42. MacDonald, H. R., S. Baschieri, R. K. Lees. 1991. Clonal expansion precedes anergy and death of Vß8+ peripheral T cells responding to staphylococcal enterotoxin B in vivo. Eur. J. Immunol. 21:1963.[Medline]
  43. Kawabe, Y., A. Ochi. 1990. Selective anergy of Vß8+, CD4+ T cells in Staphylococcus enterotoxin B-primed mice. J. Exp. Med. 172:1065.[Abstract/Free Full Text]
  44. Herrmann, T., S. Baschieri, R. K. Lees, H. R. MacDonald. 1992. In vivo responses of CD4+ and CD8+ cells to bacterial superantigens. Eur. J. Immunol. 22:1935.[Medline]
  45. Hauschildt, S., W. G. Bessler, P. Scheipers. 1993. Engagement of major histocompatibility complex class II molecules leads to nitrite production in bone marrow-derived macrophages. Eur. J. Immunol. 23:2988.[Medline]
  46. Fleming, S. D., J. J. Iandolo, S. K. Chapes. 1991. Murine macrophage activation by staphylococcal exotoxins. Infect. Immun. 59:4049.[Abstract/Free Full Text]
  47. Buyalos, R. P., E. M. Rutanen, E. Tsui, J. Halme. 1991. Release of tumor necrosis factor alpha by human peritoneal macrophages in response to toxic shock syndrome toxin-1. Obstet. Gynecol. 78:182.[Medline]
  48. Scott, M. T.. 1972. Biological effects of the adjuvant Corynebacterium parvum. II. Evidence for macrophage-T-cell interaction. Cell. Immunol. 5:469.[Medline]
  49. Alleva, D. G., C. J. Burger, K. D. Elgert. 1994. Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-{alpha} production. Role of tumor-derived IL-10, TGF-ß, and prostaglandin E2. J. Immunol. 153:1674.[Abstract]
  50. Goldbach-Mansky, R., P. D. King, A. P. Taylor, B. Dupont. 1992. A co-stimulatory role for CD28 in the activation of CD4+ T lymphocytes by staphylococcal enterotoxin B. Int. Immunol. 4:1351.[Abstract/Free Full Text]
  51. Green, J. M., L. A. Turka, C. H. June, C. B. Thompson. 1992. CD28 and staphylococcal enterotoxins synergize to induce MHC-independent T-cell proliferation. Cell. Immunol. 145:11.[Medline]
  52. Ohnishi, H., T. Tanaka, J. Takahara, M. Kotb. 1993. CD28 delivers costimulatory signals for superantigen-induced activation of antigen-presenting cell-depleted human T lymphocytes. J. Immunol. 150:3207.[Abstract]
  53. Taub, D., T. J. Rogers. 1992. Direct activation of murine T cells by staphylococcal enterotoxins. Cell. Immunol. 140:267.[Medline]
  54. Shimonkevitz, R., E. Boen, S. Malmstrom, E. Brown, J. Hurley, B. Kotzin, M. Matsumura. 1996. Delineation by use of monoclonal antibodies of the T-cell receptor and major histocompatibility complex interaction sites on the superantigen toxic shock syndrome toxin 1. Infect. Immun. 64:1133.[Abstract]
  55. Dohlsten, M., G. Hedlund, E. Å kerblom, P. A. Lando, T. Kalland. 1991. Monoclonal antibody-targeted superantigens: a different class of anti-tumor agents. Proc. Natl. Acad. Sci. USA 88:9287.[Abstract/Free Full Text]
  56. Ihle, J., U. Holzer, F. Krull, M. Dohlsten, T. Kalland, D. Niethammer, G. E. Dannecker. 1995. Antibody-targeted superantigens induce lysis of major histocompatibility complex class II-negative T-cell lines. Cancer Res. 55:623.[Abstract/Free Full Text]
  57. Lando, P. A., M. Dohlsten, G. Hedlund, E. Å kerblom, T. Kalland. 1993. T cell killing of human colon carcinomas by monoclonal-antibody-targeted superantigens. Cancer Immunol. Immunother. 36:223.[Medline]
  58. Holzer, U., W. Bethge, F. Krull, J. Ihle, R. Handgretinger, R. A. Reisfeld, M. Dohlsten, T. Kalland, D. Niethammer, G. E. Dannecker. 1995. Superantigen-staphylococcal-enterotoxin-A-dependent and antibody-targeted lysis of GD2-positive neuroblastoma cells. Cancer Immunol. Immunother. 41:129.[Medline]
  59. Kalland, T., G. Hedlund, M. Dohlsten, P. A. Lando. 1991. Staphylococcal enterotoxin-dependent cell-mediated cytotoxicity. Curr. Top. Microbiol. Immunol. 174:82.
  60. Abrahmsén, L., M. Dohlsten, S. Segrén, P. Björk, E. Jonsson, T. Kalland. 1995. Characterization of two distinct MHC class II binding sites in the superantigen staphylococcal enterotoxin A. EMBO J. 14:2978.[Medline]
  61. Hansson, J., L. Ohlsson, R. Persson, G. Andersson, N.-G. Ilbäck, M. J. Litton, T. Kalland, M. Dohlsten. 1997. Genetically engineered superantigens as tolerable antitumor agents. Proc. Natl. Acad. Sci. USA 94:2489.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Cancer Res.Home page
N. P. Singh, E. S. Yolcu, D. D. Taylor, C. Gercel-Taylor, D. S. Metzinger, S. K. Dreisbach, and H. Shirwan
A Novel Approach to Cancer Immunotherapy: Tumor Cells Decorated with CD80 Generate Effective Antitumor Immunity
Cancer Res., July 15, 2003; 63(14): 4067 - 4073.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. Zheng, A. Chen, R. E. Sterner, P. J. Zhang, T. Pan, N. Kiyatkin, and M. L. Tykocinski
Induction of Antitumor Immunity via Intratumoral Tetra-Costimulator Protein Transfer
Cancer Res., November 1, 2001; 61(22): 8127 - 8134.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
B. A. Torres, S. Kominsky, G. Q. Perrin, A. C. Hobeika, and H. M. Johnson
Superantigens: The Good, the Bad, and the Ugly
Experimental Biology and Medicine, March 1, 2001; 226(3): 164 - 176.
[Abstract] [Full Text]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wahlsten, J. L.
Right arrow Articles by Ramakrishnan, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wahlsten, J. L.
Right arrow Articles by Ramakrishnan, S.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS